

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/627,981	07/28/2003	Saul Yedgar	P-2507-US1	4110
27130 75	90 11/17/2005		EXAMINER	
	RL, LATZER & COHE	O'SULLIVAN, PETER G		
10 ROCKEFELLER PLAZA, SUITE 1001 NEW YORK, NY 10020			ART UNIT	PAPER NUMBER
•			1621	

DATE MAILED: 11/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/627,981	YEDGAR ET AL.			
Office Action Summary	Examiner	Art Unit			
•	Peter G. O'Sullivan	1621			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be time rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this communication. O (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>31 Au</u> This action is FINAL . 2b) ☐ This Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. ace except for formal matters, pro				
Disposition of Claims					
4)⊠ Claim(s) 1-7 and 19-22 is/are pending in the ap 4a) Of the above claim(s) is/are withdraw 5)□ Claim(s) is/are allowed. 6)⊠ Claim(s) 1-7 and 19-22 is/are rejected. 7)□ Claim(s) is/are objected to. 8)□ Claim(s) are subject to restriction and/or	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examiner	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	· 				
Paper No(s)/Mail Date 6) Uther:					

Application/Control Number: 10/627,981

Art Unit: 1621

Claims 1-7 and 19-22 are pending in this application. The rejections of the claims under 35. USC 101, 112 and 102(b) as well as the rejection under the judicially created doctrine of obviousness type double patenting are withdrawn in view of applicants' amendments and arguments.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-7 and 19-22 are again rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teaching of Yedgar et al., US 5,064,817, Chaikof et al., US 6,171,614, and Aoki et al., US 5,470,578, in view of Pruzanski et al., US 6,043,231, Sorgente et al., US 6,162,787 and Falk et al., US 6,022,866, for the reasons of record. Applicants' arguments have been given due consideration, but are found non-persuasive. Applicants show how each individual reference differs from the instant

Application/Control Number: 10/627,981

Art Unit: 1621

invention, but under 35 U.S.C. 103, the obviousness test is whether it would have been obvious to do what applicants' did given the teaching of the art taken as a whole. In re Metcalf et al.,157 U.S.P.Q. 423. Yedgar et al., disclose their compounds to be PLA2 inhibitors with utility in treating a wide variety of oversecretory disease states overlapping other of the references. Although the primary references do not disclose treating sepsis, Pruzanski et al. is relied on to disclose PLA2 inhibiting compounds to be useful in treating sepsis and various inflammatory disorders. Chaikof et al. disclose conjugation of a lipid or phospholipid moiety to a GAG and although applicants' point out this is via an ether bond, as opposed to an amide or ester bond, applicants' claims are not limited to conjugation via an amide or ester bond.

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/627,981

Art Unit: 1621

Page 4

Any inquiry concerning this communication should be directed to Peter G.

O'Sullivan at telephone number (571)272-0642.

PETER O'SULLIVAN PRIMARY EXAMINER GROUP 1200